Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company committed to transforming the treatment landscape for people suffering from gastrointestinal (GI) diseases related to acid. Our initial product candidate, vonoprazan, is a potassium competitive acid blocker (P-CAB), a new class of anti-secretory medicines with potential applications in GI diseases.
We are a team of highly driven pharmaceutical professionals who are passionate about our mission to address unmet needs for patients and improve their quality of life. By ensuring all voices are heard, holding ourselves accountable to be equitable and just, and authentically supporting the people and communities impacted by our work, we strive to create a sense of inclusion and belonging.
We are looking for self-motivated, creative problem solvers who are excited by the idea of working in a fast-paced start-up environment and contributing to our growth.
Location: United States, New Jersey, Florham Park
Employees: 51-200
Total raised: $140M
Founded date: 2018
Investors 7
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
| - | Hercules C... | htgc.com |
| - | RA Capital... | racap.com |
| - | Frazier Li... | frazierls.... |
| - | Abingworth... | abingworth... |
| - | Sahsen Ven... | sahsen.com |
| - | Catalys Pa... | catalyspac... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.05.2019 | - | $140M | - |
Mentions in press and media 15
| Date | Title | Description | Source |
| 07.03.2024 | Phathom Pharmaceuticals Reports Fourth Quarter and Full Year... | - | globenewsw... |
| 01.11.2022 | Phathom Pharmaceuticals Announces Placement of the Remaining... | - | globenewsw... |
| 04.05.2022 | Phathom Pharmaceuticals Announces Revenue Interest Financing... | Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonopraza... | globenewsw... |
| 03.05.2022 | Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ ... | FLORHAM PARK, N.J., May 03, 2022 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a ... | catalyspac... |
| 18.10.2021 | Phathom Pharmaceuticals Announces Positive Topline Results f... | FLORHAM PARK, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a... | catalyspac... |
| 20.09.2021 | Phathom Pharmaceuticals, Inc. Secures $200 Million Term Loan... | Phathom Pharmaceuticals, Inc. reported it has obtained a $200 million term loan facility from Hercul... | marketscre... |
| 20.09.2021 | Hercules Capital : Phathom Pharmaceuticals Secures $200 Mill... | FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),... | marketscre... |
| 16.09.2021 | Catalent Signs Commercial Supply Agreement with Phathom Phar... | As Phathom readies for the potential approval and launch of our first product, we are pleased to hav... | prweb.com/... |
| 08.09.2021 | Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Von... | With current standard of care therapies, H. pylori eradication rates have declined in the U.S. If ap... | catalyspac... |
| 29.04.2021 | Phathom Pharmaceuticals Announces Positive Topline Results f... | FLORHAM PARK, N.J., April 29, 2021 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), ... | catalyspac... |
Show more